Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akshanth R Polepally

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Clinical Pharmacology and Therapeutics|July 30, 2019
Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis PatientsAmit Khatri, Ahmed A Suleiman, Akshanth R Polepally, et al.
European Journal of Drug Metabolism and Pharmacokinetics|May 12, 2016
Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV InfectionAkshanth R Polepally, Prajakta S Badri, Doerthe Eckert, et al.
Clinical Pharmacokinetics|February 26, 2017
Clinical Pharmacokinetics of ParitaprevirRajeev M Menon, Akshanth R Polepally, Amit Khatri, et al.
Clinical Pharmacokinetics|June 18, 2016
Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b InfectionSathej M Gopalakrishnan, Akshanth R Polepally, Sven Mensing, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 5, 2020
Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis-Associated Pain: An Application of Markov ModelInsa Winzenborg, Akshanth R Polepally, Ahmed Nader, et al.
Clinical Pharmacology in Drug Development|June 17, 2016
Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without DasabuvirAkshanth R Polepally, Sandeep Dutta, Beibei Hu, et al.
Clinical Pharmacokinetics|September 3, 2015
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV TherapyPrajakta S Badri, Jennifer R King, Akshanth R Polepally, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 10, 2026
Semi-Mechanistic PK/PD Modeling of Platelets and Spleen Volume With Navitoclax in Combination With Ruxolitinib in Patients With MyelofibrosisAkshanth R Polepally, Aline Goebel, Maulik Patel, et al.
Clinical Pharmacokinetics|March 23, 2016
Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I StudiesAkshanth R Polepally, Sven Mensing, Amit Khatri, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 18, 2020
Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated PainAhmed Abbas Suleiman, Ahmed Nader, Insa Winzenborg, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Clinical Pharmacology and Therapeutics|July 30, 2019
Exposure-Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis PatientsAmit Khatri, Ahmed A Suleiman, Akshanth R Polepally, et al.
European Journal of Drug Metabolism and Pharmacokinetics|May 12, 2016
Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV InfectionAkshanth R Polepally, Prajakta S Badri, Doerthe Eckert, et al.
Clinical Pharmacokinetics|February 26, 2017
Clinical Pharmacokinetics of ParitaprevirRajeev M Menon, Akshanth R Polepally, Amit Khatri, et al.
Clinical Pharmacokinetics|June 18, 2016
Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b InfectionSathej M Gopalakrishnan, Akshanth R Polepally, Sven Mensing, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 5, 2020
Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis-Associated Pain: An Application of Markov ModelInsa Winzenborg, Akshanth R Polepally, Ahmed Nader, et al.
Clinical Pharmacology in Drug Development|June 17, 2016
Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without DasabuvirAkshanth R Polepally, Sandeep Dutta, Beibei Hu, et al.
Clinical Pharmacokinetics|September 3, 2015
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV TherapyPrajakta S Badri, Jennifer R King, Akshanth R Polepally, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 10, 2026
Semi-Mechanistic PK/PD Modeling of Platelets and Spleen Volume With Navitoclax in Combination With Ruxolitinib in Patients With MyelofibrosisAkshanth R Polepally, Aline Goebel, Maulik Patel, et al.
Clinical Pharmacokinetics|March 23, 2016
Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I StudiesAkshanth R Polepally, Sven Mensing, Amit Khatri, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 18, 2020
Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated PainAhmed Abbas Suleiman, Ahmed Nader, Insa Winzenborg, et al.
Pageof 4